Lenz Therapeutics’ eye disease drugs meet main goal of late-stage study – ET HealthWorld | Pharma


0

[ad_1]

The company said it has identified one of the drugs, LNZ100, as its lead product candidate as it showed statistically significant improvement in patients’ ability to see details at a distance of 20 feet at three hours post-treatment.

  • Updated On Apr 3, 2024 at 05:49 PM IST

London: Lenz Therapeutics said on Wednesday its experimental drugs to treat loss of near vision met the main goal of a late-stage study, sending its shares up nearly 23 per cent before the bell.

The company said it has identified one of the drugs, LNZ100, as its lead product candidate as it showed statistically significant improvement in patients’ ability to see details at a distance of 20 feet at three hours post-treatment.

The other drug, LNZ101, also showed similar results but did not show superiority to LNZ100, the San Diego, California-based company said.

Lenz plans to submit a marketing application for LNZ100 in the United States in mid-2024.

(Reporting by Sneha S K in Bengaluru; Editing by Shilpi Majumdar)

  • Published On Apr 3, 2024 at 05:42 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles


Scan to download App


[ad_2]

Source link


Like it? Share with your friends!

0
Shafiq

0 Comments

Your email address will not be published. Required fields are marked *